T cell gene therapy to treat immunodeficiency

Area of Science:

• Immunology
• Gene Therapy
• Cell Therapy

Background:

• Therapeutic T cell applications have advanced significantly, including CAR-T cell therapy.
• Primary immunodeficiencies are genetic disorders impacting immune system development and function.
• Current definitive treatments include hematopoietic stem cell transplantation and gene therapy.

Purpose of the Study:

• To review T cell gene addition and gene-editing strategies for primary immunodeficiencies.
• To highlight clinical experience and preclinical findings in T cell-based gene therapy.
• To explore the potential of autologous gene-modified T cell therapy for lymphoid compartment disorders.

Main Methods:

• Review of clinical and preclinical studies on T cell gene therapy for primary immunodeficiencies.
• Analysis of gene addition and gene-editing approaches targeting specific immune defects.
• Focus on diseases affecting T cell immunity, including CD40 ligand deficiency, IPEX syndrome, X-linked lymphoproliferative disease, and HLH.

Main Results:

• Autologous gene-modified T cell therapy presents a potential cure for certain primary immunodeficiencies.
• Restoration of T cell function through gene therapy can address defects in immune response, regulation, and cytotoxicity.
• Clinical and preclinical data suggest significant value in applying T cell gene therapy to these conditions.

Conclusions:

• T cell gene therapy offers a promising therapeutic avenue for primary immunodeficiencies.
• Restoring functional T cells via gene modification can correct immune defects and improve patient outcomes.
• Further development of T cell gene therapy holds potential for treating a range of lymphoid-specific genetic disorders.